312-93-6Relevant articles and documents
Eudragit E100 as a drug carrier: The remarkable affinity of phosphate ester for dimethylamine
Guzman,Manzo,Olivera
, p. 2424 - 2433 (2012)
Therapeutic agents containing phosphate groups in their molecules have increasing therapeutic impact. The object of this study was to characterize the cationic polyelectrolyte Eudragit E100 (EuE100) as a carrier for drugs containing phosphate groups, using dexamethasone phosphate (DP) as a model. A series of EuE100-DP complexes was obtained by acid-base reaction in which DP neutralized 12.5-75% of the basic groups of EuE100. The solids obtained after solvent evaporation revealed by spectroscopic characterization the complete reaction between the components through the ionic interaction between the amine groups of EuE100 and the phosphate groups of DP. The reversibility of the counterion condensation, evaluated through the proton-withdrawing effect produced by the ionic exchange generated by titration with NaCl, showed a remarkable high affinity between EuE100 and DP. In line, drug delivery in bicompartimental Franz cells toward water as receptor medium was very slow (2% in 6 h). However, it was increased as water was replaced by NaCl solution, which upon diffusion generates ionic exchange. A sustained release of DP with noticeable zero order kinetics accounted for a remarkable high affinity, mainly due to the electrostatic attraction. The release rate remains constant regardless of the saline concentration of the media. Besides, the delivery control is maintained even in gastric simulated fluid, a property not informed previously for EuE100 complexes.
Trihydrate dexamethasone sodium phosphate compound and pharmaceutical composition preparation thereof
-
Paragraph 0045; 0047; 0048, (2019/01/23)
The invention discloses a trihydrate dexamethasone sodium phosphate compound and a pharmaceutical composition preparation thereof. Each mole of dexamethasone sodium phosphate compound contains 3 molesof water. The trihydrate dexamethasone sodium phosphate compound which is high in purity, good in stability, high in solubility and not prone to moisture absorption is prepared by controlling the pHvalue, the devitrification temperature and the devitrification solvent system of a dexamethasone sodium phosphate solution by an inventor. The pharmaceutical composition preparation is an injection oreye drops prepared from the trihydrate dexamethasone sodium phosphate compound.
Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates
Kern, Jeffrey C.,Cancilla, Mark,Dooney, Deborah,Kwasnjuk, Kristen,Zhang, Rena,Beaumont, Maribel,Figueroa, Isabel,Hsieh, SuChun,Liang, Linda,Tomazela, Daniela,Zhang, Jeffrey,Brandish, Philip E.,Palmieri, Anthony,Stivers, Peter,Cheng, Mangeng,Feng, Guo,Geda, Prasanthi,Shah, Sanjiv,Beck, Andrew,Bresson, Damien,Firdos, Juhi,Gately, Dennis,Knudsen, Nick,Manibusan, Anthony,Schultz, Peter G.,Sun, Ying,Garbaccio, Robert M.
, p. 1430 - 1445 (2016/02/18)
As part of an effort to examine the utility of antibody-drug conjugates (ADCs) beyond oncology indications, a novel pyrophosphate ester linker was discovered to enable the targeted delivery of glucocorticoids. As small molecules, these highly soluble phosphate ester drug linkers were found to have ideal orthogonal properties: robust plasma stability coupled with rapid release of payload in a lysosomal environment. Building upon these findings, site-specific ADCs were made between this drug linker combination and an antibody against human CD70, a receptor specifically expressed in immune cells but also found aberrantly expressed in multiple human carcinomas. Full characterization of these ADCs enabled procession to in vitro proof of concept, wherein ADCs 1-22 and 1-37 were demonstrated to afford potent, targeted delivery of glucocorticoids to a representative cell line, as measured by changes in glucocorticoid receptor-mediated gene mRNA levels. These activities were found to be antibody-, linker-, and payload-dependent. Preliminary mechanistic studies support the notion that lysosomal trafficking and enzymatic linker cleavage are required for activity and that the utility for the pyrophosphate linker may be general for internalizing ADCs as well as other targeted delivery platforms.